Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29965675 | 0.79 | MAPT (0.46) | ALDH1A1GAASMN1; SMN2ATML3MBTL1 | |
| SCHEMBL3319620 | 0.78 | ALDH1A1 (0.47) | ALDH1A1POLBTSHRMEN1KMT2A | |
| SCHEMBL29965262 | 0.72 | MAPT (0.44) | ALDH1A1GAASMN1; SMN2ATML3MBTL1 | |
| SCHEMBL23727122 | 0.70 | MAPT (0.47) | ALDH1A1SMN1; SMN2POLBATML3MBTL1 | |
| SCHEMBL9367156 | 0.69 | ALDH1A1 (0.38) | ALDH1A1GAASMN1; SMN2L3MBTL1TSHR | |
| SCHEMBL9215253 | 0.68 | GAA (0.52) | ALDH1A1GAASMN1; SMN2MEN1KMT2A | |
| SCHEMBL7522044 | 0.67 | PKM (0.45) | ALDH1A1SMN1; SMN2POLBL3MBTL1MEN1 | |
| SCHEMBL19718789 | 0.67 | HDAC8 (0.41) | ALDH1A1GAAPOLBTHRBATM | |
| SCHEMBL19360211 | 0.67 | L3MBTL1 (0.39) | ALDH1A1GAATHRBATML3MBTL1 | |
| Hydrochloric Acid SCHEMBL8430562 | 0.66 | KMT2A (0.35) | ALDH1A1GAATHRBATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367696-B2 | Aza-bridged-ring compound | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367696-B2 | Aza-bridged-ring compound | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100105658-A1 | AZA-BRIDGED-RING COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100105658-A1 | AZA-BRIDGED-RING COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105658-A1 | AZA-BRIDGED-RING COMPOUND | CHRM3, CHRM1, CHRM2 | ALDH1A1 2006/4885GAA 4265/4885SMN1; SMN2 4664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.